September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis – 1 year follow up
Author Affiliations & Notes
  • Joao J Nassaralla
    Ophthalmology, Instituto de Olhos de Goiania and UnB, Goiania, Goias, Brazil
  • Joao J Nassaralla
    Ophthalmolgy, UFG, Goiania, Brazil
  • Arthur Amaral Nassaralla
    Ophthalmology, FMSLM, Campinas, Brazil
  • Footnotes
    Commercial Relationships   Joao Nassaralla, None; Joao Nassaralla, None; Arthur Nassaralla, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3039. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Joao J Nassaralla, Joao J Nassaralla, Arthur Amaral Nassaralla; Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis – 1 year follow up. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3039.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Aflibercept (Eylea®) and Ranibzumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. Lucentis (R) is administered in the form of smaller molecules, which is thought to give R an advantage over Eylea (A) in its ability to penetrate the eye's halt abnormal blood vessel growth contributing to advanced macular degeneration and scarring that causes blindness. They may have a role in treating ocular disorders involving fibrovascular proliferation. To determine and compare whether intraocular A and R decreases rubeosis iridis (RI) in patients with neovascular glaucoma (NVG).

Methods : The study included 24 eyes with secondary NVG due to proliferative diabetic retinopathy (n=20) or ischemic vessel occlusion (n=4). 12 eyes received an intraocular injection (IOI) of 2.00 mg of A and 12 eyes 1.25mg R, from May 2013 to September 2015. IOI was performed in topical anaesthesia either in the anterior chamber (n=18) or via pars plana intravitreally (n=6). RI was investigated prospectively by iris biomicroscopy. An expanded informed consent with an off-label use waiver and explanation letter was reviewed with all patients. The follow up was performed 1, 3, 7, 15 days, 1, 6 months and 1, year after IOI.

Results : Degree of RI decreased significantly (p<0.01) within 1 week after application of both drugs. The improvement was maintained for at least 4 weeks when was did panretinal photocoagulation (PRP). After 1 year only 3 eyes (2 A and 1 R) development reccurent RI, when was did more injection and more PRP. The two drugs are about equal in their effectiveness. An inflammatory response with fibrinous reaction and pseudohypopyon was observed in 1 case (with R) one day after surgery. The reaction persisted only 2 days.

Conclusions : The preliminary conclusion is that the two drugs are about equal in their effectiveness, but A or ranibizumab R, may provide an additional strategy to the treatment of R. Its long term effect and impact on NVG has to be determined. The number of patients in this pilot study was limited to make any specific treatment recommendations, but the favorable results suggest further study is needed. More studies are needed to evaluate the effect of this medication prior to clinical use.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.